Prescription Pattern of Aromatase Inhibitors in the Adjuvant Setting in Germany – Final Results of a Survey Among German Breast Cancer Specialists

Lüftner, Diana; Henschke, P.; Pollmann, D.; Schildhauer, S.; Possinger, K.

doi:10.1159/000089339

Cited by 6 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The neuroendocrine differentiation correlates with an expression of estrogen and progesterone receptors in the majority of the well- and moderately differentiated tumors and in > 50% of poorly differentiated/small cell carcinomas. Prognosis for tumors with neuroendocrine differentiation is related to conventional histological tumor grading and staging, but not to the neuroendocrine differentiation per se [16]. However, in selected series of neuroendocrine carcinomas of the breast, the prognosis was reported as either better [17] or worse [18] than that in control patients.…”

Section: Special Subtypes Of Invasive Breast Carcinomamentioning

confidence: 99%

A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition

2013

View full text Add to dashboard Cite

The WHO Classification of Tumors of the Breast, 4th edition, is an update to the 3rd edition that was published in 2003, and covers all neoplastic and preneoplastic lesions of the breast. Changes to the 4th edition include new aspects and changes to the terminology that reflect our present-day knowledge of these lesions. Definitions for histopathological diagnosis are complemented by a description of clinical features, epidemiology, macroscopy, genetics, and prognostic and predictive features. In this review of the WHO classification, we have focused on invasive carcinomas, precursor lesions, and some benign epithelial proliferations.

show abstract

Section: Special Subtypes Of Invasive Breast Carcinomamentioning

confidence: 99%

A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition

2013

View full text Add to dashboard Cite

show abstract

“…These trials demonstrated superiority of the AIs and delivered the evidence needed to introduce these drugs in standard treatment. The trials have been extensively reviewed in the past and the major original publications as wells as some of the reviews are cited here for further reading [23][24][25][26][27][28][29][59][60][61][62][63][64][65][66][67][68].…”

Section: Phase III Clinical Trials In Aromatase Researchmentioning

confidence: 99%

Aromatase inhibitors: from bench to bedside and back

Geisler

2007

Breast Cancer

View full text Add to dashboard Cite

The development of the novel "third generation" aromatase inhibitors (anastrozole, letrozole) and inactivators (exemestane) is one of the most successful contemporary achievements in breast cancer therapy. While clinical studies evaluated toxicity and efficacy in metastatic disease, the endocrine effects of multiple compounds were evaluated in parallel, identifying the most potent aromatase inhibitors based on estrogen deprivation in plasma and tissue samples in addition to "total body aromatase inhibition" in vivo. Thus, "translational" studies have been of vital importance identifying the unique characteristics of these drugs. While first- and second generation aromatase inhibitors inhibit estrogen synthesis in vivo by up to 90%, third generation compounds like anastrozole, exemestane and letrozole were shown to cause > or = 98% aromatase inhibition in humans. The present paper summarises and discusses the "translational research" that provided the background for the implementation of the third generation aromatase inhibitors and inactivators into large clinical trials and later on in clinical use. Finally, some of the major topics of currently ongoing translational research programs are presented. These programs focus on aromatase regulation in different tissues, mechanisms of resistance to aromatase inhibition and strategies to overcome resistance like combined therapy with aromatase inhibitors and intracellular signal transduction inhibitors.

show abstract

“…Since 1998, breast cancer patients have been treated with considerable success with Herceptin ® (trastuzumab, an anti-HER2 humanized monoclonal antibody), a recombinant antibody designed to block signaling through the HER2 receptor [9][10][11]. The most important prerequisite for the optimal efficacy of trastuzumab-based therapy remains a very strict selection of those patients with tumors that have HER-2/neu overexpression [12].…”

Section: Genomicsmentioning

confidence: 99%

‘Omics‘-Based Imaging in Cancer Detection and Therapy

Oehr

2006

Personalized Medicine

View full text Add to dashboard Cite

Genomics, proteomics and metabolomics, which can be also summarized as 'omics', have become increasingly inter-related with imaging. Gene expression profiling may be assessed using high-density microarrays for the detection of overexpression patterns, followed by the development of histochemical assays. Next, antibodies to the gene-corresponding proteins (for example, receptors) can be produced, leading to serum immunoassays for follow-up, as well as antibody-guided in vivo imaging or therapy. In vivo imaging for cancer detection and/or therapy can be performed by applying nonlabeled antibodies, by using radiolabeled antibodies for detection using single-photon tomography or positron emission tomography (PET), or by other tracers, for example, for magnetic resonance imaging tomography (MRI, MRT). Protein profiles from protein chips can be derived from mass maps obtained through mass spectrometry (MS). Electrophoretic separation of proteins has also been combined with MS to produce a two-dimensional assignment of proteins within a complex mixture. Overexpression of tumor-related proteins can be used for the development of antibodies to develop noninvasive assays that can be used in the screening of risk groups as a basis for further investigation by invasive imaging methods. Metabolomic profiling by nuclear magnetic resonance spectroscopy can be applied for the detection of biomarkers of the metabolome. Metabolite profiles in cells, tissues, and organisms can be generated with nuclear magnetic resonance spectroscopy and MS. Metabolic information provided by magnetic resonance spectroscopic imaging (MRSI) combined with the anatomical information provided by MRI can significantly improve the assessment of cancer location and extent, and cancer aggressiveness. Biomarkers found by MRSI can lead to new PET tracers. This article provides examples and discusses some of the recent achievements to bring forward novel strategies for the diagnosis and therapy of cancer.

show abstract

Prescription Pattern of Aromatase Inhibitors in the Adjuvant Setting in Germany – Final Results of a Survey Among German Breast Cancer Specialists

Cited by 6 publications

References 11 publications

A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition

A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition

Aromatase inhibitors: from bench to bedside and back

‘Omics‘-Based Imaging in Cancer Detection and Therapy

Contact Info

Product

Resources

About